The primary therapeutic role of this product is to provide supportive benefits by addressing deficits in two vital nutrients, Calcium and Vitamin C (Sodium Ascorbate), which is relevant for managing nutritional gaps for supportive benefit.

This combination is commonly used as part of supportive management for conditions characterized by insufficient Calcium levels, such as the risk of hypocalcemia (low calcium in the body), and for Vitamin C deficiency (scurvy). It plays a role in supportive therapy as an adjunct to therapy for skeletal issues like osteoporosis, rickets, and osteomalacia.

“The provision of essential minerals and vitamins supports long-term functional stability and general well-being.”

By supplying these nutrients, the preparation contributes to maintaining functional stability and offers supportive relief that may assist patients in coping more steadily with deficiency-related symptoms. The product helps manage symptom clusters that include muscle cramps, generalized fatigue, joint tenderness, and poor wound healing and other manifestations related to tissue health. It is often applied in situations requiring supplemental intake to compensate for dietary inadequacies or during periods of increased physiological need.

---

Quick Fact: Relief for Deficiency-Related Symptoms

The supplement is applied when symptoms related to systemic imbalance become noticeable, contributing to the easing of the overall symptom load associated with chronic nutritional deficits.

Regulatory References

1. NIH MedlinePlus overview of Vitamin C

This section outlines the official eligibility and non-eligibility requirements for using Ca-C 1000 Calvive, as established by government regulatory authorities (e.g., EMA, FDA). Eligibility is strictly determined by specific health conditions and age demographics, primarily due to the high content of Calcium and Vitamin C.

Official Eligibility Status

Classification	Population/Condition
Approved Population	Adults and Adolescents (typically over 12 years of age) for standard labeled use.
Contraindicated	Patients with Hypercalcemia (high blood calcium) or Hypercalciuria (excessive urinary calcium excretion).
Contraindicated	Patients with a history of Nephrolithiasis (kidney stones) or Severe Renal Impairment.
Contraindicated	Known Hypersensitivity to the active substances or any excipients.

Use Limitations and Restrictions

Use of this supplement is subject to limitations based on specific physiological or health contexts:

• Pediatric Use: The product is not recommended for general use in young children (e.g., under 12) due to the high dose, unless under explicit medical guidance.
• Organ Function: Moderate Renal Impairment requires conditional use with close medical monitoring of calcium and phosphate levels. The co-administration of Cardiac Glycosides also necessitates close supervision.
• Pregnancy/Lactation: Use is generally permitted, but intake must not exceed the established Recommended Daily Allowance (RDA) for Calcium and Vitamin C, as defined by health authorities.

Interactions with other medicines and products

It is important to inform your doctor or pharmacist about all other medications, supplements, and herbal products you are currently taking, as Ca-C 1000 Calvive (Calcium and Ascorbic Acid) can interact with several compounds, potentially affecting their absorption or efficacy.

---

Notable Drug Interactions

• Oral Tetracycline and Quinolone Antibiotics: Calcium can significantly decrease the absorption of these antibiotics (e.g., ciprofloxacin, doxycycline). To minimize this interaction, these antibiotics should be taken at least 2 hours before or 4-6 hours after taking Ca-C 1000 Calvive.
• Thiazide Diuretics: Medicines like hydrochlorothiazide reduce the excretion of calcium by the kidneys. Concomitant use with Ca-C 1000 Calvive may increase the risk of hypercalcemia (high calcium levels in the blood).
• Corticosteroids: Long-term use of systemic corticosteroids (e.g., prednisone) can decrease calcium absorption. This may necessitate an increase in calcium supplementation.
• Cardiac Glycosides: In patients taking cardiac glycosides (e.g., digoxin), administration of calcium can increase the risk of arrhythmias (irregular heartbeats). Close medical monitoring is required.
• Bisphosphonates and Levothyroxine: Calcium can also interfere with the absorption of bisphosphonates (used for osteoporosis) and levothyroxine (thyroid hormone replacement). A dosing separation of several hours is typically recommended.

---

Food Interactions

Foods rich in oxalic acid (e.g., spinach, rhubarb) or phytic acid (e.g., whole grains, cereals) can inhibit the absorption of calcium. Avoid taking Ca-C 1000 Calvive within two hours of consuming large amounts of these foods.

How Ca-C 1000 Calvive Works

Regulation of Skeletal and Dental Mineralization

This domain covers the incorporation of calcium ions ( Ca^2+) into the hydroxyapatite matrix of bone and teeth, which are the main reservoirs of calcium in the body. The mechanism regulates the availability of Ca^2+ for incorporation into the hydroxyapatite lattice, contributing to the crystalline structure of skeletal tissues.

---

Modulation of Neuromuscular Excitability

This involves the action of free calcium ions ( Ca^2+) at the cell membrane level, where they are critical cofactors for nerve impulse transmission and muscle contraction, including cardiac muscle. This engagement modifies cell membrane permeability to cations, influencing the action potential threshold.

---

Enhancement of Coagulation Cascades

Ca^2+ acts as an essential enzyme cofactor for multiple clotting factors, notably those involved in the initiation and amplification of the blood coagulation cascade. This facilitates the conversion of prothrombin to thrombin, thereby accelerating the cross-linking of fibrin monomers.

---

Support for Antioxidant and Redox Systems

Vitamin C (Ascorbic Acid) functions as a powerful reductant to neutralize reactive free radicals throughout the body. This action involves donating electrons to neutralize reactive oxygen species (ROS), resulting in their chemical inactivation.

Official Administration Guidelines

Ca-C 1000 Calvive is an effervescent tablet formulated for oral administration as a solution. The instructions provided define the required method, dosage, and timing for its correct use.

---

Dosing and Preparation

Administration Scope	Instruction
Standard Dose	Adults and children should take one effervescent tablet (1000 mg) once per day.
Preparation	The tablet must be completely dissolved in a glass of water (approximately 200 ml) before ingestion. Do not swallow or chew the tablet.
Timing	The prepared solution must be drunk immediately upon dissolution.

---

Administration Constraints

• Food Timing: This medicine may be taken with or without food. However, it must not be taken within two hours of eating foods known to be high in oxalic or phytic acid, such as spinach, rhubarb, or whole cereals, as this can affect the absorption.
• Pediatric Use: Use in young children (under 3 years old) should not exceed one week unless under the advice of a healthcare professional. It should not be given to newborn babies (up to 4 weeks old) unless recommended by a doctor, due to excipient content.
• Renal Impairment: Patients with impaired renal function should only take calcium salts under medical supervision, with monitoring of their serum calcium and phosphate levels.

Research Evidence / Overview of Studies for Ca-C 1000 Calvive

The research landscape for this combination product, containing Calcium and Sodium Ascorbate (Vitamin C), is primarily defined by studies examining the nutritional and physiological function of these two essential nutrients. The evidence is evaluated based on its type and relevance to the clinical contexts where the supplement is studied, adhering strictly to official and peer-reviewed scientific literature.

---

Evidence for Use in Nutritional Deficiency and Supplementation

This section summarizes the evidence base, which consists largely of population surveys, public health data, and large-scale observational studies, focusing on how these studies measured nutrient intake levels and the status of both Calcium and Vitamin C in various cohorts.

Population-level data show patterns related to supplement use and overall nutrient status, finding that the use of dietary supplements has been observed in some studies to be associated with individuals meeting recommended nutrient intake targets. The available data, however, is largely observational, meaning it describes associations rather than proving cause-and-effect. This evidence is generally limited in establishing long-term, direct clinical health outcomes.

---

Evidence for Skeletal Health Support

This part will outline the research landscape for the role of the active ingredients in bone health, summarizing the systematic reviews and clinical trials (often including Vitamin D) that have investigated outcomes such as changes in Bone Mineral Density ( BMD) and the assessment of fracture risk.

Systematic reviews and trials described patterns observed in the studies, reporting measurements of BMD that were evaluated following supplementation. Observational studies also show patterns related to higher Vitamin C status and BMD measurements, particularly when Calcium intake was adequate. The specific, independent role of Vitamin C in this context requires further focused research.

---

What Remains Uncertain in the Research Landscape

Key limitations include that high-quality, long-term comparative evidence is lacking for the precise clinical benefits of this specific Calcium and Vitamin C combination versus other single-nutrient or multi-nutrient formulations. Furthermore, while the short-term impact on certain episodic outcomes has been examined, long-term effects on sustained functional stability are not fully established. Research efforts continue to explore these areas to provide a more comprehensive understanding of the combined effects studied. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Common questions about Ca-C 1000 Calvive (FAQ)

Q: Does tamsulosin (Flomax) cause drowsiness, and should I avoid driving?

A: Official drug information reports dizziness, lightheadedness, and somnolence (drowsiness) as potential side effects of tamsulosin. Regulatory documents state that patients should be aware of the risk of fainting (syncope) and consider avoiding activities like operating heavy machinery or driving until they know how tamsulosin affects them.

Q: Can I drink alcohol while taking metoprolol (Lopressor/Toprol-XL)?

A: Official product information notes that alcohol consumption may increase the level of metoprolol in the body. Alcohol can also intensify side effects such as drowsiness and dizziness, which are potential effects of metoprolol. The official label information advises consulting a healthcare provider regarding alcohol consumption, as caution may be necessary while taking this medication.

Q: Is tamsulosin safe to take long-term for benign prostatic hyperplasia (BPH)?

A: Clinical studies supporting the approval of tamsulosin have evaluated its effectiveness and safety over continuous treatment periods of up to four to six years for the symptoms of BPH. Official information indicates that the medicine was generally well-tolerated and was found to maintain its efficacy over these extended periods in the studied population.

Q: Can metoprolol be used in children under 12?

A: According to official regulatory documents, metoprolol (both immediate-release and extended-release forms) is indicated for use in pediatric patients 6 years of age and older to reduce high blood pressure. Safety and effectiveness have not been established for this indication in children younger than 6 years of age.

Q: Does tamsulosin treat the cause of BPH or just the symptoms?

A: Tamsulosin is officially indicated for treating the signs and symptoms of benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, which helps to improve the flow of urine.

How to Store and Dispose of Ca-C 1000 Calvive?

The official storage requirements for Ca-C 1000 Calvive effervescent granules focus on maintaining the stability of the product. The granules must be stored in the original container and the tube must be kept tightly closed to protect the product from humidity and light.

The stated shelf-life for the product is 3 years, provided it is stored correctly under these designated conditions. For safety, the container must be kept out of the reach of children.

Disposal of any unused medicinal product or waste material must be executed in accordance with local requirements for pharmaceutical waste.